

Merck & Co. Inc
Merck National Service Center
P.O. Box 4, ZB-/11
West Point, PA 19486-0004



July 1, 2009

XXXXXXXXXXXXX
XXXXXXXXXXXXX
XXXXXXXXXXXXX

Dear XXXXXXX,

This is in response to your letter regarding MMR® II (Measles, Mumps and Rubella Virus Vaccine Live) and the monovalent vaccines ATTENUVAX® (measles vaccine), MUMPSVAX® (mumps vaccine) and MERUVAX® (rubella vaccine).

At Merck, our fundamental responsibility is discovering, developing and delivering innovative medicines and vaccines that can make a difference in people's lives and create a healthier future. We believe that fulfilling this responsibility in a sustainable manner entails high ethical standards and a culture that values honesty, integrity and transparency in all that we do.

We have carefully considered the perspectives about human cell lines that you mention in your letter, and believe our use of these cells to prepare vaccines recommended by the *Advisory Committee on Immunization Practices* (ACIP) is consistent with our company's high ethical standards and commitment to public health.

As you know, we are not currently taking orders or producing the monovalent vaccines because our manufacturing capacity is needed to meet global supply needs for MMR II. In the future, we plan to resume production of these monovalent vaccines, though we do not anticipate these monovalents will be available for at least two years.

Thank you for sharing your perspective on this important topic.

Sincerely,

The Merck National Service Center

Service Request Number: 1-3303685502